Massih Ningarhari

Patients with cirrhosis are at competing risk of liver-related events and mortality, which may impact the oncological outcomes of GI cancers treated with cytotoxic chemotherapy. Careful multidisciplinary management is warranted when treating these patients. 1 INTRODUCTION Gastrointestinal (GI) cancers are frequent in patients with cirrhosis and represent a leading cause of mortality.

Abstract Telomerase is a key enzyme for cell survival that prevents telomere shortening and the subsequent cellular senescence that is observed after many rounds of cell division. In contrast, inactivation of telomerase is observed in most cells of the adult liver. Absence of telomerase activity and shortening of telomeres has been implicated in hepatocyte senescence and the development of cirrhosis, a chronic liver disease that can lead to hepatocellular carcinoma (HCC) development.